Focus on Sarcoidosis
The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP)
Cutoffs for most of the phenotypic measures used to assess sarcoidosis distinguished groups of sarcoidosis patients with differing OIPs over the subsequent 6 months. The patients’ global assessment of their disease was the most accurate of these measures.The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study
To study how demographic differences impact disease manifestation of sarcoidosis using the WASOG tool in a large multicentric study.Steroids for sarcoidosis: How much and for how long?
Most clinicians agree that corticosteroids are the first choice for treatment for symptomatic pulmonary sarcoidosis [1,2]. Prednisone is one of the most commonly used corticosteroids, with the usual initial dose being 20–40 mg daily [3,4]. However, the specific dose and rationale for such a dose is unclear. Early studies of corticosteroids were associated with quite variable doses and duration of therapy. In some studies, 60 mg for one month and then slowly tapered for more than a year [5] while others gave 15 mg for three months total [6].
